Project Grant R01HL174622
- This $1,436,586 Project Grant awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research study titled "Identifying Response Defining Mechanisms for Biological Therapies in Severe Asthma (INSIGHTS): Assessing the Role of CD4-CTLs." The study, led by researchers at the San Diego Biomedical Research Institute, aims to evaluate the impact of a novel subset of cytotoxic CD4+ T cells (CD4-CTLs) on the efficacy...
- This Project Grant award of $2,456,717.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by Thomas Jefferson University's Sidney Kimmel Medical College to exploit emerging ideas in G protein-coupled receptor (GPCR) biology and pharmacology to treat asthma. The key objectives are to: 1) identify novel GPCR targets and targeting molecules that regulate airway smooth muscle contraction and proliferation, 2) delineate the...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $636,843 to The Regents of the University of California, San Francisco (UCSF) to conduct research on targeting the stromal niche for tissue-resident lymphocytes in asthma. The key objectives are to: 1) characterize a targetable stromal factor that alters immune cell accumulation in the lung, and 2) define the downstream effects of these immune cells on...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate and target the role of the Siglec-9 receptor on mast cells. The $612,917 award to Seattle Children's Research Institute will investigate how Siglec-9 and its ligands modulate mast cell function, with the goal of identifying new therapeutic strategies to inhibit mast cell-associated disorders like urticaria,...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to investigate the role of circadian rhythms in regulating immune responses in the human airway epithelium, particularly in the context of asthma. The $154,980 award to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, will fund three specific aims over a 5-year period from September 1, 2025 to August 31, 2030. The...
- This Project Grant award, funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research by Dr. Tristan Kooistra at Massachusetts General Hospital (MGH) to investigate the role of airway macrophages in lung homeostasis and disease. The $170,640 award, with a period of performance from August 15, 2025 to May 31, 2030, will enable Dr. Kooistra to leverage his expertise in innate immune signaling, type 2 immunity, and 3D imaging to study...
- This Project Grant award of $207,500 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research to investigate the role of the MIF/CD74 pathway in influencing the function of group 2 innate lymphoid cells (ILC2s) and their contribution to the development of airway hyperreactivity, a key aspect of asthma pathogenesis. The goal is to gain mechanistic insights that could...
- This Project Grant award of $1,395,741 from the Department of Homeland Security supports research by the University of Colorado-Denver to investigate mast cell activation as a common mechanism of pulmonary toxicity caused by chemical threat agents. The project, funded under the Trans-NIH Research Support program (CFDA 93.310), will confirm the in vivo contribution of mast cells to pulmonary injury and inflammation resulting from exposure to the chemical threat agents chloropicrin and...
- This Project Grant award of $133,221 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Brigham & Women's Hospital focused on chronic airway inflammatory diseases like chronic rhinosinusitis and asthma. The key objectives are to 1) develop computational capabilities to identify fundamental insights into the treatment and prevention of airway diseases, and 2) train the next generation of patient-oriented researchers in this...
- This federal Project Grant award of $801,648 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to uncover the molecular mechanisms responsible for the protective effects of early endotoxin exposure against allergic asthma. The University of Illinois, as the awardee, will pursue three specific research aims: 1) Investigate the molecular mechanisms of MIZ1 downregulation by endotoxin and its role in mediating the protective effect against allergic...
DETERMINING DRIVERS OF MAST CELL EXPANSION AND FUNCTION DURING HUMAN AIRWAY DISEASE - PROJECT SUMMARY/ABSTRACT: MAST CELLS (MCS) EXPAND WITHIN THE AIRWAY EPITHELIUM AND SUB-EPITHELIUM DURING PREVALENT AND BURDENSOME HUMAN RESPIRATORY DISEASE, INCLUDING ASTHMA AND NASAL POLYPOSIS, WHERE THEY ARE THOUGHT TO PLAY A CENTRAL ROLE IN DISEASE PATHOBIOLOGY. MCS TAKE ON DISCRETE PROTEASE EXPRESSION PROFILES IN EACH LOCATION, WITH SUP-EPITHELIAL MCS CO-EXPRESSING TRYPTASE AND CHYMASE (MCTC) WHILE EPITHELIAL MCS EXPRESS TRYPTASE ALONE (MCT). NEITHER THE MECHANISMS UNDERLYING THIS EXPANSION, THE SIGNALS DIRECTING THE EPITHELIAL AND SUB-EPITHELIAL MC PHENOTYPES, NOR THE DIFFERENTIAL CONTRIBUTION OF MC PHENOTYPES TO TISSUE INFLAMMATION ARE WELL UNDERSTOOD. THIS APPLICATION FOCUSES ON UNDERSTANDING THE MECHANISMS THROUGH WHICH AIRWAY TISSUE STRUCTURAL CELLS DIFFERENTIALLY DIRECT THE EXPANSION AND DIFFERENTIATION OF MC PROGENITORS (MCPS), BASED ON PRELIMINARY STUDIES IDENTIFYING A CENTRAL ROLE FOR FIBROBLASTS AND EPITHELIAL CELLS IN BOTH PROCESSES. THIS PROPOSAL TESTS THE CENTRAL HYPOTHESIS THAT MC HYPERPLASIA IN INFLAMED HUMAN AIRWAY MUCOSA IS DRIVEN BY THE RECRUITMENT OF MCPS EXHIBITING A ROBUST PROLIFERATIVE CAPACITY, AND THAT THE PROLIFERATION AND DIFFERENTIATION OF THESE RECRUITED MCPS TOWARDS THE HISTOCHEMICALLY RECOGNIZED MCT AND MCTC SUBSETS ARE DRIVEN BY KEY SIGNALS SECRETED BY AIRWAY STRUCTURAL CELLS. A RELATED HYPOTHESIS IS THAT THE RESULTING INTRAEPITHELIAL AND SUBEPITHELIAL MC PHENOTYPES ARE MAINTAINED THROUGH A NETWORK OF TRANSCRIPTION FACTORS REGULATED BY THESE TISSUE STROMAL-DERIVED SIGNALS, AND THAT SIGNAL NUCLEOTIDE POLYMORPHISMS IN THESE TRANSCRIPTION FACTORS INCREASE RISK OF DEVELOPING AIRWAY DISEASE. AIM 1 OF THIS PROPOSAL EVALUATES MCP CONCENTRATION IN HUMAN SINONASAL TISSUE ACROSS DISEASE ENDOTYPES, DETERMINING THE RELATIONSHIP BETWEEN RECRUITED MCP AND THE PROLIFERATIVE POPULATION OF MCS WE PREVIOUSLY IDENTIFIED IN NASAL POLYPOSIS. AIM 2 OF THIS PROPOSAL TESTS THE IMPACT OF A SERIES OF CANDIDATE STROMAL-DERIVED LIGANDS ON DIRECTING MCP PROLIFERATION AND DIFFERENTIATION USING CRISPR/CAS9 GENE EDITING. AIM 3 PROBES THE TRANSCRIPTION FACTOR NETWORK UNDERLYING MC POLARIZATION VIA SHRNA KNOCKDOWN AND EVALUATES THE IMPACT OF KEY ASTHMA- ASSOCIATED SINGLE NUCLEOTIDE POLYMORPHISMS IN ONE SUCH TRANSCRIPTION FACTOR ON INTRAEPITHELIAL MC DIFFERENTIATION. COMPLETION OF THESE AIMS WILL GREATLY EXPAND OUR UNDERSTANDING OF THE PATHWAYS THROUGH WHICH MCS ARE CAPABLE OF INFLUENCING TISSUE INFLAMMATION AND THE MECHANISM(S) THROUGH WHICH THESE PATHWAYS ARE REGULATED BY THEIR TISSUE MICROENVIRONMENT.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $708.6k | 8/22/25 | ||
| Not listed | $0 | 8/18/25 | ||
| Not listed | $716.0k | 6/28/24 |